Patents Assigned to Agios Pharmaceutical, Inc.
  • Methods of evaluating patients using E-cadherin and vimentin
    Patent number: 9618514
    Abstract: Methods for the selection, evaluation, and/or treatment of a patient having cancer with an inhibitor of a glutamine-utilizing enzyme or a glutamine-depleting agent, by evaluating E-cadherin or vimentin expression are disclosed.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: April 11, 2017
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventors: Sung Eun Choe, Jonathan Hurov, Danielle Ulanet
  • Therapeutically active compounds and their methods of use
    Patent number: 9579324
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: February 28, 2017
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy M. Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
  • PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
    Publication number: 20170014396
    Abstract: Provided are compounds and pharmaceutical compositions useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound or pharmaceutical composition described herein.
    Type: Application
    Filed: March 13, 2015
    Publication date: January 19, 2017
    Applicant: AGIOS PHARMACEUTICALS, INC
    Inventor: Chong-Hui Gu
  • Therapeutically active compositions and their methods of use
    Patent number: 9512107
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: December 6, 2016
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
  • Therapeutically active compositions and their methods of use
    Patent number: 9474779
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: October 25, 2016
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
    Publication number: 20160304556
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Application
    Filed: June 29, 2016
    Publication date: October 20, 2016
    Applicant: AGIOS PHARMACEUTICALS, INC
    Inventors: Janeta Popovici-Muller, Jeffrey O. Saunders, Francesco G. Salituro, Zhenwei Cai, Ding Zhou, Shunqi Yan
  • Therapeutic compounds and compositions and their use as PKM2 modulators
    Patent number: 9458132
    Abstract: Compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: October 4, 2016
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventors: Giovanni Cianchetta, Janeta Popovici-Muller, Jeffrey O. Saunders, Robert Zahler
  • THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE
    Publication number: 20160264621
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.
    Type: Application
    Filed: March 9, 2016
    Publication date: September 15, 2016
    Applicant: AGIOS PHARMACEUTICALS, INC
    Inventors: Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy M. Travins, Shunqi Yan
  • Methods of using pyruvate kinase activators
    Patent number: 9403792
    Abstract: Described herein are compounds that activate pyruvate kinase, for use in a method for increasing lifetime of the red blood cells, for regulating 2,3-diphosphoglycerate levels in blood and for treating sickle cell anemia.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: August 2, 2016
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventor: Shin-San M. Su
  • Pyruvate kinase activators for use in therapy
    Patent number: 9404081
    Abstract: Described herein are methods for using compounds that activate pyruvate kinase.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: August 2, 2016
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventor: Shin-San Michael Su
  • Methods of using pyruvate kinase activators
    Patent number: 9388164
    Abstract: Described herein are methods for using compounds that activate pyruvate kinase.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: July 12, 2016
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventor: Shin-San M. Su
  • Therapeutic compounds and compositions
    Patent number: 9365545
    Abstract: Compounds of general formula I: and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: June 14, 2016
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventors: Giovanni Cianchetta, Janeta Popovici-Muller, Robert Zahler, Sheldon Cao, Xiaolei Wang, Zhixiong Ye
  • Bicyclic PKM2 activators
    Patent number: 9328077
    Abstract: Compounds and compositions comprising compounds that activate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that activate PKM2 in the treatment of cancer.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: May 3, 2016
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventors: Francesco G. Salituro, Jeffrey O. Saunders
  • Compounds and their methods of use
    Patent number: 9303002
    Abstract: Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: April 5, 2016
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan
  • N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators
    Patent number: 9221792
    Abstract: Compounds of general Formula (I), and compositions comprising compounds of general formula I that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: December 29, 2015
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventors: Francesco G. Salituro, Jeffrey O. Saunders, Shunqi Yan
  • Therapeutic compounds and compositions
    Patent number: 9199968
    Abstract: Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: December 1, 2015
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Francesco G. Salituro, Jeffrey O. Saunders, Shunqi Yan
  • Pyruvate kinase activators for use in therapy
    Patent number: 9193701
    Abstract: Described herein are methods for using compounds that activate pyruvate kinase.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: November 24, 2015
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventor: Shin-San M. Su
  • Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
    Patent number: 9181231
    Abstract: Described herein are methods for using compounds that activate pyruvate kinase.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: November 10, 2015
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventor: Shin-San M. Su
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS
    Publication number: 20150307473
    Abstract: Compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
    Type: Application
    Filed: November 8, 2013
    Publication date: October 29, 2015
    Applicant: AGIOS PHARMACEUTICALS, INC
    Inventors: Giovanni Cianchetta, Janeta Popovici-Muller, Jeffrey O. Saunders, Robert Zahler
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20150299115
    Abstract: Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Cancers that are treatable by the compounds of the invention are glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, and non-Hodgkin's lymphoma (NHL).
    Type: Application
    Filed: October 11, 2013
    Publication date: October 22, 2015
    Applicant: AGIOS PHARMACEUTICALS, INC
    Inventors: Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan